beacon: for rare diseases ltd
beacon: for rare diseases ltd Company Information
Company Number
08174973
Next Accounts
Oct 2025
Industry
Other human health activities
Shareholders
-
Group Structure
View All
Contact
Registered Address
66 devonshire road, cambridge, CB1 2BL
Website
http://findacure.org.ukbeacon: for rare diseases ltd Estimated Valuation
Pomanda estimates the enterprise value of BEACON: FOR RARE DISEASES LTD at £297.4k based on a Turnover of £523.3k and 0.57x industry multiple (adjusted for size and gross margin).
beacon: for rare diseases ltd Estimated Valuation
Pomanda estimates the enterprise value of BEACON: FOR RARE DISEASES LTD at £233.2k based on an EBITDA of £53.9k and a 4.32x industry multiple (adjusted for size and gross margin).
beacon: for rare diseases ltd Estimated Valuation
Pomanda estimates the enterprise value of BEACON: FOR RARE DISEASES LTD at £477.4k based on Net Assets of £191.5k and 2.49x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Beacon: For Rare Diseases Ltd Overview
Beacon: For Rare Diseases Ltd is a live company located in cambridge, CB1 2BL with a Companies House number of 08174973. It operates in the other human health activities sector, SIC Code 86900. Founded in August 2012, it's largest shareholder is unknown. Beacon: For Rare Diseases Ltd is a established, small sized company, Pomanda has estimated its turnover at £523.3k with high growth in recent years.
Upgrade for unlimited company reports & a free credit check
Beacon: For Rare Diseases Ltd Health Check
Pomanda's financial health check has awarded Beacon: For Rare Diseases Ltd a 5 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 1 areas for improvement. Company Health Check FAQs
4 Strong
4 Regular
1 Weak
Size
annual sales of £523.3k, make it in line with the average company (£646.1k)
£523.3k - Beacon: For Rare Diseases Ltd
£646.1k - Industry AVG
Growth
3 year (CAGR) sales growth of 17%, show it is growing at a faster rate (7.4%)
17% - Beacon: For Rare Diseases Ltd
7.4% - Industry AVG
Production
with a gross margin of 38.6%, this company has a comparable cost of product (38.6%)
38.6% - Beacon: For Rare Diseases Ltd
38.6% - Industry AVG
Profitability
an operating margin of 9.6% make it more profitable than the average company (5.5%)
9.6% - Beacon: For Rare Diseases Ltd
5.5% - Industry AVG
Employees
with 10 employees, this is below the industry average (17)
10 - Beacon: For Rare Diseases Ltd
17 - Industry AVG
Pay Structure
on an average salary of £30.8k, the company has an equivalent pay structure (£26.2k)
£30.8k - Beacon: For Rare Diseases Ltd
£26.2k - Industry AVG
Efficiency
resulting in sales per employee of £52.3k, this is equally as efficient (£48.1k)
£52.3k - Beacon: For Rare Diseases Ltd
£48.1k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Beacon: For Rare Diseases Ltd
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Beacon: For Rare Diseases Ltd
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Beacon: For Rare Diseases Ltd
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 2079 weeks, this is more cash available to meet short term requirements (114 weeks)
2079 weeks - Beacon: For Rare Diseases Ltd
114 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 2.5%, this is a lower level of debt than the average (25.8%)
2.5% - Beacon: For Rare Diseases Ltd
25.8% - Industry AVG
BEACON: FOR RARE DISEASES LTD financials
Beacon: For Rare Diseases Ltd's latest turnover from January 2024 is £523.3 thousand and the company has net assets of £191.5 thousand. According to their latest financial statements, Beacon: For Rare Diseases Ltd has 10 employees and maintains cash reserves of £191.9 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Jan 2024 | Jan 2023 | Jan 2022 | Jan 2021 | Jan 2020 | Jan 2019 | Jan 2018 | Jan 2017 | Jan 2016 | Jan 2015 | Jan 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 523,301 | 324,211 | 269,865 | 324,970 | 186,665 | 262,615 | 275,667 | 340,172 | 332,415 | 100,434 | 41,052 |
| Other Income Or Grants | |||||||||||
| Cost Of Sales | |||||||||||
| Gross Profit | |||||||||||
| Admin Expenses | |||||||||||
| Operating Profit | |||||||||||
| Interest Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-Tax Profit | 44,473 | -65,299 | -48,478 | 128,821 | -7,630 | 55,458 | 7,499 | -10,569 | 27,970 | 40,825 | 18,414 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | 44,473 | -65,299 | -48,478 | 128,821 | -7,630 | 55,458 | 7,499 | -10,569 | 27,970 | 40,825 | 18,414 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Profit | 44,473 | -65,299 | -48,478 | 128,821 | -7,630 | 55,458 | 7,499 | -10,569 | 27,970 | 40,825 | 18,414 |
| Employee Costs | 308,347 | 226,439 | 172,905 | 129,170 | 105,294 | 105,806 | 96,568 | 100,176 | 66,533 | 26,141 | 7,172 |
| Number Of Employees | 10 | 8 | 6 | 5 | 4 | 4 | 4 | 4 | 3 | 2 | 1 |
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Jan 2024 | Jan 2023 | Jan 2022 | Jan 2021 | Jan 2020 | Jan 2019 | Jan 2018 | Jan 2017 | Jan 2016 | Jan 2015 | Jan 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 4,012 | 4,175 | 1,907 | 1,659 | 742 | 198 | 601 | 413 | 246 | 1,302 | 2,086 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 4,012 | 4,175 | 1,907 | 1,659 | 742 | 198 | 601 | 413 | 246 | 1,302 | 2,086 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5,000 | 11,500 | 3,378 | 0 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 359 | 407 | 231 | 229 | 229 | 4,045 | 221 | 1,946 | 1,503 | 203 | 199 |
| Cash | 191,913 | 146,871 | 214,159 | 263,385 | 136,056 | 140,200 | 86,974 | 72,489 | 78,436 | 55,916 | 17,629 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 192,272 | 147,278 | 214,390 | 263,614 | 136,285 | 144,245 | 87,195 | 79,435 | 91,439 | 59,497 | 17,828 |
| total assets | 196,284 | 151,453 | 216,297 | 265,273 | 137,027 | 144,443 | 87,796 | 79,848 | 91,685 | 60,799 | 19,914 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 0 | 0 | 0 | 84 | 572 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 4,800 | 4,442 | 3,987 | 4,401 | 4,488 | 4,846 | 3,657 | 3,208 | 4,476 | 1,560 | 1,500 |
| total current liabilities | 4,800 | 4,442 | 3,987 | 4,485 | 5,060 | 4,846 | 3,657 | 3,208 | 4,476 | 1,560 | 1,500 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total liabilities | 4,800 | 4,442 | 3,987 | 4,485 | 5,060 | 4,846 | 3,657 | 3,208 | 4,476 | 1,560 | 1,500 |
| net assets | 191,484 | 147,011 | 212,310 | 260,788 | 131,967 | 139,597 | 84,139 | 76,640 | 87,209 | 59,239 | 18,414 |
| total shareholders funds | 191,484 | 147,011 | 212,310 | 260,788 | 131,967 | 139,597 | 84,139 | 76,640 | 87,209 | 59,239 | 18,414 |
| Jan 2024 | Jan 2023 | Jan 2022 | Jan 2021 | Jan 2020 | Jan 2019 | Jan 2018 | Jan 2017 | Jan 2016 | Jan 2015 | Jan 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||
| Operating Profit | |||||||||||
| Depreciation | 3,524 | 3,047 | 1,647 | 1,015 | 569 | 403 | 401 | 440 | 1,056 | 1,145 | 1,027 |
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | -48 | 176 | 2 | 0 | -3,816 | 3,824 | -6,725 | -6,057 | 9,422 | 3,382 | 199 |
| Creditors | 0 | 0 | -84 | -488 | 572 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 358 | 455 | -414 | -87 | -358 | 1,189 | 449 | -1,268 | 2,916 | 60 | 1,500 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | |||||||||||
| Investing Activities | |||||||||||
| capital expenditure | 0 | 0 | |||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | 0 | 0 | |||||||||
| Financing Activities | |||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | |||||||||||
| interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from financing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash and cash equivalents | |||||||||||
| cash | 45,042 | -67,288 | -49,226 | 127,329 | -4,144 | 53,226 | 14,485 | -5,947 | 22,520 | 38,287 | 17,629 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 45,042 | -67,288 | -49,226 | 127,329 | -4,144 | 53,226 | 14,485 | -5,947 | 22,520 | 38,287 | 17,629 |
beacon: for rare diseases ltd Credit Report and Business Information
Beacon: For Rare Diseases Ltd Competitor Analysis
Perform a competitor analysis for beacon: for rare diseases ltd by selecting its closest rivals, whether from the HUMAN HEALTH AND SOCIAL WORK ACTIVITIES sector, other small companies, companies in CB1 area or any other competitors across 12 key performance metrics.
beacon: for rare diseases ltd Ownership
BEACON: FOR RARE DISEASES LTD group structure
Beacon: For Rare Diseases Ltd has no subsidiary companies.
Ultimate parent company
BEACON: FOR RARE DISEASES LTD
08174973
beacon: for rare diseases ltd directors
Beacon: For Rare Diseases Ltd currently has 5 directors. The longest serving directors include Dr Anthony Hall (Aug 2012) and Ms Edna Kissmann (Aug 2012).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Dr Anthony Hall | Netherlands | 63 years | Aug 2012 | - | Director |
| Ms Edna Kissmann | 75 years | Aug 2012 | - | Director | |
| Mr Andrew Milligan | United Kingdom | 59 years | Aug 2012 | - | Director |
| Mrs Sophie Costello | England | 46 years | Oct 2019 | - | Director |
| Ms Joanne Pisani | England | 60 years | Oct 2019 | - | Director |
P&L
January 2024turnover
523.3k
+61%
operating profit
50.4k
0%
gross margin
38.7%
+0.21%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
January 2024net assets
191.5k
+0.3%
total assets
196.3k
+0.3%
cash
191.9k
+0.31%
net assets
Total assets minus all liabilities
beacon: for rare diseases ltd company details
company number
08174973
Type
Private Ltd By Guarantee w/o Share Cap
industry
86900 - Other human health activities
incorporation date
August 2012
age
13
incorporated
UK
ultimate parent company
accounts
Total Exemption Full
last accounts submitted
January 2024
previous names
findacure foundation (January 2022)
accountant
MATTHEW PETTIFER
auditor
-
address
66 devonshire road, cambridge, CB1 2BL
Bank
CO-OPERATIVE BANK PLC
Legal Advisor
-
beacon: for rare diseases ltd Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to beacon: for rare diseases ltd.
beacon: for rare diseases ltd Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for BEACON: FOR RARE DISEASES LTD. This can take several minutes, an email will notify you when this has completed.
beacon: for rare diseases ltd Companies House Filings - See Documents
| date | description | view/download |
|---|
